Astrazeneca Plc Adr Stock Fundamentals
| AZN Stock | USD 77.60 1.09 1.42% |
AstraZeneca PLC ADR fundamentals help investors to digest information that contributes to AstraZeneca PLC's financial success or failures. It also enables traders to predict the movement of AstraZeneca Stock. The fundamental analysis module provides a way to measure AstraZeneca PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AstraZeneca PLC stock.
At this time, AstraZeneca PLC's EBITDA is very stable compared to the past year. As of the 14th of March 2025, Total Operating Expenses is likely to grow to about 35.6 B, while Operating Income is likely to drop about 5.2 B. AstraZeneca | Select Account or Indicator |
AstraZeneca PLC ADR Company Current Valuation Analysis
AstraZeneca PLC's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current AstraZeneca PLC Current Valuation | 258.34 B |
Most of AstraZeneca PLC's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AstraZeneca PLC ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
AstraZeneca Current Valuation Historical Pattern
Today, most investors in AstraZeneca PLC Stock are looking for potential investment opportunities by analyzing not only static indicators but also various AstraZeneca PLC's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of AstraZeneca PLC current valuation as a starting point in their analysis.
AstraZeneca PLC Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, AstraZeneca PLC ADR has a Current Valuation of 258.34 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is significantly lower than that of the firm.
AstraZeneca PLC ADR Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining AstraZeneca PLC's current stock value. Our valuation model uses many indicators to compare AstraZeneca PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AstraZeneca PLC competition to find correlations between indicators driving AstraZeneca PLC's intrinsic value. More Info.AstraZeneca PLC ADR is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.45 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for AstraZeneca PLC ADR is roughly 2.23 . At this time, AstraZeneca PLC's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AstraZeneca PLC's earnings, one of the primary drivers of an investment's value.AstraZeneca Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AstraZeneca PLC's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AstraZeneca PLC could also be used in its relative valuation, which is a method of valuing AstraZeneca PLC by comparing valuation metrics of similar companies.AstraZeneca PLC is currently under evaluation in current valuation category among its peers.
AstraZeneca PLC Current Valuation Drivers
We derive many important indicators used in calculating different scores of AstraZeneca PLC from analyzing AstraZeneca PLC's financial statements. These drivers represent accounts that assess AstraZeneca PLC's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of AstraZeneca PLC's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 131.2B | 166.5B | 209.9B | 210.9B | 203.5B | 252.3B | |
| Enterprise Value | 143.8B | 191.0B | 232.9B | 233.7B | 228.2B | 268.2B |
AstraZeneca PLC ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, AstraZeneca PLC's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to AstraZeneca PLC's managers, analysts, and investors.Environmental | Governance | Social |
AstraZeneca Fundamentals
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0788 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 258.34 B | ||||
| Shares Outstanding | 3.1 B | ||||
| Shares Owned By Institutions | 17.49 % | ||||
| Number Of Shares Shorted | 15.46 M | ||||
| Price To Earning | 103.39 X | ||||
| Price To Book | 6.19 X | ||||
| Price To Sales | 4.39 X | ||||
| Revenue | 54.07 B | ||||
| Gross Profit | 44.44 B | ||||
| EBITDA | 17.12 B | ||||
| Net Income | 8.69 B | ||||
| Cash And Equivalents | 4.52 B | ||||
| Cash Per Share | 1.46 X | ||||
| Total Debt | 30.11 B | ||||
| Debt To Equity | 0.89 % | ||||
| Current Ratio | 0.81 X | ||||
| Book Value Per Share | 26.30 X | ||||
| Cash Flow From Operations | 11.86 B | ||||
| Short Ratio | 2.79 X | ||||
| Earnings Per Share | 2.25 X | ||||
| Price To Earnings To Growth | 0.92 X | ||||
| Target Price | 85.1 | ||||
| Number Of Employees | 94.3 K | ||||
| Beta | 0.16 | ||||
| Market Capitalization | 237.21 B | ||||
| Total Asset | 104.03 B | ||||
| Retained Earnings | 3.16 B | ||||
| Working Capital | (2.04 B) | ||||
| Current Asset | 16.01 B | ||||
| Current Liabilities | 14.87 B | ||||
| Annual Yield | 0.02 % | ||||
| Five Year Return | 2.99 % | ||||
| Net Asset | 104.03 B | ||||
| Last Dividend Paid | 3.1 |
About AstraZeneca PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AstraZeneca PLC ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AstraZeneca PLC ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 134.1 M | 140.8 M | |
| Total Revenue | 54.1 B | 56.8 B | |
| Cost Of Revenue | 10.2 B | 6.6 B | |
| Stock Based Compensation To Revenue | 0.01 | 0.01 | |
| Sales General And Administrative To Revenue | 0.37 | 0.31 | |
| Research And Ddevelopement To Revenue | 0.25 | 0.14 | |
| Capex To Revenue | 0.08 | 0.06 | |
| Revenue Per Share | 34.80 | 36.54 | |
| Ebit Per Revenue | 0.18 | 0.22 |
Pair Trading with AstraZeneca PLC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.Moving against AstraZeneca Stock
| 0.97 | EMBC | Embecta Corp | PairCorr |
| 0.85 | SRDX | SurModics | PairCorr |
| 0.84 | WST | West Pharmaceutical | PairCorr |
| 0.84 | SMLR | Semler Scientific | PairCorr |
| 0.82 | MLTX | MoonLake Immunotherapeuti | PairCorr |
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out AstraZeneca PLC Piotroski F Score and AstraZeneca PLC Altman Z Score analysis. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.567 | Dividend Share 3.1 | Earnings Share 2.25 | Revenue Per Share | Quarterly Revenue Growth 0.238 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.